Despite multiple suggested therapies no truly effective treatment for systemic sclerosis (scleroderma) has yet emerged.' 2Tantalising hints have developed from recent studies emphasising the microvascular pathogenesis of scleroderma34 and from our first report5 of successful treatment of scleroderma renal crisis with antihypertensive treatment. Both we and others observing patients on dialysis69 or who have survived renal crisis5 have noted dramatic remission of skin disease. These observations fit a theoretical model of vascular pathogenesis, involving microvascular hypertension or a capillary leak syndrome. In this model extrusion of fluid from the microvasculature into tight tissue compartments causes first an oedematous reaction, Raynaud's phenomenon, and telangiectasia, and subsequently leads to intimal sclerosis of small arterioles, distal ischaemic difficulties, and tissue atrophy.34 This model has suggested the possibility that antihypertensive treatment might be effective in patients not in renal crisis, and indeed a number of patients have been empirically managed in this way.
To examine the role of antihypertensive treatment in nonhypertensive scleroderma patients we performed a 2-year randomised prospective doubleblind trial comparing alpha-methyl dopa and propranolol versus placebo capsules. Our selection of these 2 antihypertensive agents was principally Accepted for publication 20 July 1983. Correspondence to Dr J. F. Fries. empirical, these being the agents reported most commonly in anecdotal reports of skin remission following successful treatment of scleroderma renal crisis.'
Patients and methods
Twenty-eight patients with a diagnosis of systemic sclerosis (scleroderma) were asked, with their families, to give informed consent, and after doing so were divided into pairs of patients matched for decade of age, duration of disease within 5 years, and disease severity. Randomisation was performed within each pair of patients, one being assigned to the drug and one to the placebo group. A therapist measured the blood pressure on each visit and adjusted the dose of the antihypertensive medications. Another physician, the investigator, blindly assessed clinical results at 0, 6, 12, 18 and 24 months. The investigator was blind to the drugs given, to the laboratory values, to the blood pressure recordings, and to any therapeutic adjustments which might have been performed by the therapist, who was also blind to the particular drug. The dependent variables consisted of a skin map of involved areas, photographs of hand and face, haematocrit (packed cell volume), serum creatinine, disability index, finger-to-palm distance, interincisor distance, physician's overall impression, and patient's overall impression. Power calculations suggested that there were too few patients in the study to make a definitive result likely. Table 2 , were quite similar between groups. Since more drop-outs occurred in the active drug group, the placebo group retained a slightly more seriously affected group of individuals, creating a slight bias in favour of the group on active drug. Table 2 summarises the initial and final findings of the major dependent variables. The mean diastolic blood pressure was 14 mmHg different, the active drug group having declined by 13 mmHg while the placebo group increased by 1. This difference was clinically and statistically significant (Wilcoxon rank sum test on the differences between initial and final values, p<0.05), as was systolic blood pressure. Of the remaining variables no statistically significant results were obtained. Finger-to-distal-palmarcrease measurements and disability index10 showed a trend toward the placebo, while interincisor distance, patients' and physicians' impressions, and serum creatinine showed a slight trend toward the active drug. None of these trends were clinically important. Table 3 summarises the number of patients improved, the same, or worse on the active drug or placebo regimens. Again, there were no statistically significant differences. The trend favoured placebo in finger-to-distal-palmar-crease measurements on the left, and in the disability index scores, and favoured the active drug group in the other parameters. However, no clinically or statistically significant findings
were present. Table 4 shows progression of disability scores over time. We present these data to indicate the slow progression of disability in scleroderma, and the positive direction of changes in the early months of a trial. This same trend was observed among physicians' observations such as finger-to-palm distance and interincisor distance.
Discussion
This was an informative study in terms of the natural history of scleroderma and in terms of experimental design for studies of treatment affecting scleroderma, although disappointing in terms of finding an effective treatment for this disease. Overall, both groups improved slightly, with both subjective and objective markers. There were no statistically significant differences and no clinically meaningful trends between the 2 groups, except for blood pressure, which was reduced in the group on antihypertensive drug.
The study demonstrates a favourable natural history of scleroderma over the medium term of 2 years. We believe that this suggests a positive effect of inclusion in a study of patients with an 'untreatable' disease. There is a large and objective placebo effect, and this effect carries over into the patient's disability and into objective measures of disease. This phenomenon has been previously observed in studies of intra-articular saline, which proves remarkably effective (as effective as intra-arterial reserpine) in the healing of scleroderma skin ulcers and the minimisation of symptoms due to Raynaud's phenomenon.1" It suggests that therapeutic benefit may be afforded by relatively frequent and 'positive' visits of the patient to an understanding physician.
The study design worked well. A randomised controlled trial can be performed successfully in progressive systemic sclerosis, despite difficulties in precision of endpoints and the necessity for a long period of observation. Better dependent variables should be sought; these might include the total skin score recommended by Medsger et al.2 and perhaps an observation of hair regrowth on forearms, which appeared to us to be a sensitive index of which patients were doing well during this study.
Randomised controlled trials in scleroderma will require 50 ' 4 is the common denominator in successful antihypertensive treatment of scleroderma renal crisis, as it is with ordinary malignant hypertension, and that the newer agents have merit only to the degree that they may on occasion prove to be more effective at blood pressure reduction. This study was based on the observation of dermal remission after alpha-methyl dopa and propranolol maintenance of patients in scleroderma renal crisis for up to 12 years. Nonhypertensive patients do not appear to undergo dermal remission with these drugs. 
